Why the study?
Does recombinant human activated protein C upregulate COX-2 expression and prostacyclin release in human umbilical vein endothelial cells?
Population
Human umbilical vein endothelial cells (HUVEC)
Comparison
Recombinant human activated protein C at… vs Zymogen protein C in equimolar concentrations or…
Design
Preclinical
Follow-up
3-9 hours (in vitro)
Authors
Loading...
Suggests a mechanism for rhAPC endothelial effects; leaves open clinical translation pending human studies.
Does recombinant human activated protein C upregulate COX-2 expression and prostacyclin release in human umbilical vein endothelial cells?
rhAPC upregulates COX-2 expression and prostacyclin production in human endothelial cells via EPCR and PAR-1, providing a potential molecular mechanism for its microcirculatory benefits.
Horn et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: